Global Asthma and COPD Drugs Market 2020-2026
発行: Orion Market Research Pvt Ltd
Global Asthma and COPD Drugs Market Size, Share & Trends Analysis Report by Disease Type(Asthma and COPD), By Application (Cardiology, Orthopedics, General Surgery &Anesthesia, Neurology Urology, Others) and Forecast 2020-2026
The global asthma and COPD drugs market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of patients with asthma and COPD coupled with growing clinical trials on asthma and COPD drugs. Changing lifestyle of the people is a major cause of respiratory diseases among people. Trend of smoking, drinking alcohol and ill eating activity are increasing among the people which is a major risk for the development of various respiratory related diseases. As per COPD Foundation of the US, top three causes of COPD are environmental factor, smoking and genetic factor. COPD is mostly occurred in the people of age above 40 and having a history of smoking. About 90% of the COPD patients in the US have smoking history. Therefore lifestyle changes further increases the number of cases of respiratory diseases that further contribute in the market growth.
The global asthma and COPD drugs market is segmented on the basis of disease type and drug class. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have a considerable share in the global market owing to the high number of cases of asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. Based on geography, the global asthma and COPD drugs market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global asthma and COPD drugs market.
The companies which are contributing to the growth of the global asthma and COPD drugs market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Grifols, S.A., GlaxoSmithKline PLC, Pfizer Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.
The market study of the global asthma and COPD drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report is intended for asthma and COPD drugs providers, end-user companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
The Report Covers: